| Biopharmaceutical products are the key to the future | | | | • By covering all the three major segments of the |
| of the pharmaceutical market. Even before the market | | | | biopharma market, the report gives a better |
| stagnation seen in 2009 due to the recession, | | | | perspective of the contribution of biopharma to the |
| conventional pharmaceuticals were facing drastic | | | | management of some major diseases than would be |
| consequences from the loss of patent cover for | | | | gleaned from studying only a single product type. |
| many blockbusters, and the continued failure of the | | | | Key Market Issues |
| R&D departments in big pharma to produce | | | | • Monoclonal antibodies are forecast to grow at a |
| replacement candidates. | | | | CAGR approaching 10% over the next five years, |
| Although the conventional, small-molecule segment of | | | | driven largely by good results in the clinic |
| the market will continue to hold a larger share, their | | | | • Cancers and immune-related inflammatory |
| growth is expected to be in low single figures, while | | | | diseases will continue to be leading iuses of Mabs |
| biopharma products are forecast to grow at rates up | | | | during the five-year forecast period |
| to 10% per annum. | | | | • New indications offer the prospect of major |
| This report analyses the three main components of | | | | market growth for cytokines; these include cancers |
| the biopharma market – monoclonal antibodies, | | | | and inflammatory diseases |
| therapeutic proteins and vaccines – to show why | | | | • Other therapeutic proteins such as growth |
| these groups have such a positive future. It provides | | | | factors, coagulation factors and erythropoietins, have |
| the most up-to-date discussion of the whole | | | | limited opportunities for growth through excpanding |
| biopharma market and explores new clinical indications | | | | indications, and depend instead on product |
| beyond those already targeted. | | | | improvements |
| Key features of this report | | | | Key findings from this report |
| • Monoclonal antibodies will build on recent market | | | | • In terms of market size, therapeutic proteins are |
| growth as new product candidates come onstream | | | | the leaders, but monoclonal antibodies (MAbs) are the |
| and new indications are confirmed, extending the | | | | fastest growing sector |
| usefulness of Mabs beyond cancers and autoimmune | | | | • Cancer still ranks high among targets for new |
| disease to CNS conditions, infections and others. | | | | MAb development, along with treatments for |
| • The Therapeutic Proteins class will continue to be | | | | inflammation/immune related diseases including |
| dominated by hematopoietic growth factor products | | | | rheumatoid arthritis and multiple sclerosis |
| for cancer-related neutropenia and anemia. | | | | • Cytokines in advanced development include |
| • Cytokines are another important contributor to the | | | | treatments for cancers, benign prostatic hyperplasia, |
| Therapeutic Proteins sector, and new uses for them | | | | gout and inflammatory conditions such as Crohn's |
| are under investigation, including cancers, benign | | | | disease. |
| prostatic hyperplasia, gout, wound healing and | | | | • By the end of 2009 there were 29 monoclonal |
| inflammatory diseases such as Crohn's. | | | | antibodies approved and marketed for therapeutic use. |
| • Buoyancy in the Vaccines sector is driven by | | | | This product class is now approaching maturity. |
| anxiety over bioterrorism, the ongoing risk of a global | | | | • Therapeutic protein products which have been |
| influenza pandemic and new targets for prevention. | | | | success stories include insulin, erythropoietin, growth |
| • The prospect of therapeutic vaccines, especially | | | | hormone, the interferons, and the fusion protein Enbrel |
| against cancers, is another major driver in the vaccines | | | | (etanercept) |
| market. | | | | Key questions answered |
| Scope of this report | | | | • What indications will be the main market drivers |
| • The report gives a realistic picture of the | | | | for Mabs during the next five years? |
| strengths and limitations of the biopharma marketplace, | | | | • What are the most important market trends in the |
| indicating those product groups whose strengths are | | | | vaccines market? |
| set to last while avoiding over-optimistic forecasts of | | | | • Will the biopharma market perform any better |
| growth over the next five years. | | | | than the overall pharma market during the next five |
| • In terms of R&D activity, the report aims to | | | | years, and why? |
| give the reader a perspective on the important | | | | • Which segments of the therapeutic protein |
| research avenues now being pursued, while updating | | | | market are likely to see the best growth? |
| the reader with an overview of recent R&D | | | | • What are the major drivers for M&A activity |
| developments . | | | | in the biopharma market? |